CD274 and small cell lung carcinoma: with the success of PD-L1 inhibitors Atezolizumab and Durvalumab in Impower133 study and CASPIAN study,6,7 it is proved that PD-L1 monoclonal antibody combined with standard first-line chemotherapy can significantly prolong the survival time of patients with extensive SCLC.